COVID-19与骨髓瘤:当前及未来的启示
本文讨论COVID-19大流行对骨髓瘤诊疗各环节的影响,当前重点是降低感染COVID-19及感染后遗症的风险。作者提出后疫情时代医疗交付不会恢复原状,应投资新策略以使治疗更具成本效益和更贴合患者。
要点
- 大流行影响骨髓瘤诊疗的各个方面,当前重点是降低感染COVID-19及感染后遗症的风险。
- 后疫情时代医疗交付不会恢复原状,应投资新策略以优化患者结局。
- 若积极应对后疫情环境的挑战,患者治疗可能比之前更具成本效益且更贴合个体。
核心结论
- 后疫情时代骨髓瘤诊疗不会恢复原状,应投资新策略以为患者提供最佳可能结局。
主要发现
- 大流行已影响骨髓瘤诊疗的各个方面,当前焦点是降低感染COVID-19及感染后遗症的风险。
- 作者提出若积极应对后疫情环境将出现的挑战,患者所接受的治疗可能比之前更具成本效益且更贴合个体。
临床怎么用
- 作者认为后疫情时代医疗交付不会恢复原状,当前应投资新策略以为患者提供最佳可能结局。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The pandemic has affected every aspect of myeloma care. Immediate focus is minimising risk of contracting coronavirus disease 2019 (COVID-19) and the sequelae of infection. However, what does the future hold for our patients? What lessons will be taken forward to tackle myeloma in the fiscally constrained future? If we embrace the challenges that will emerge in the post-pandemic environment, the treatment delivered to patients could be more cost-effective and better tailored than before. Healthcare delivery post-COVID-19 will not return to how it was, and now is the time to invest in novel strategies to deliver the best possible outcomes for patients.
引用
- Freeman CL, Mikhael J. COVID-19 and myeloma: what are the implications for now and in the future? Br J Haematol. 2020. PMID: 32428242. doi:10.1111/bjh.16815
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。